This article is commissioned and funded by Chiesi for UK-based healthcare professionals for an educational purpose. It does not constitute clinical advice for any specific patient. Clinical decisions ...

Apogee Therapeutics, Inc. (NASDAQ: APGE) on Tuesday shared interim data from the Phase 1b trial of zumilokibart (APG777) in patients with mild-to-moderate asthma. The data covers 19 adult patients ...

Asthma is one of the most common chronic diseases in India. In my practice, I see a pattern: most patients suffer not because asthma is untreatable, but because their everyday habits work quietly ...

In the first randomized controlled trial to investigate the use of a 2-in-1 inhaler as the sole reliever therapy for children aged 5 to 15, an international team found the combined treatment to be ...

Findings from a trial comparing the real-world effectiveness of asthma inhalers could reshape how children with asthma are treated. In the first randomized controlled trial to investigate the use of a ...

Waves similar to those produced by earthquakes need not be destructive. A new study shows that reproducing surface acoustic waves on a tiny scale can blast a drug-filled solution into a fine mist for ...

Inhalers that combine providing immediate relief with a longer-term preventative effect are already recommended as the standard treatment for mild asthma among people aged 12 and above in the UK, US ...

The findings suggest that better, proactive models are needed to coordinate school asthma care, according to investigators ...

New research reveals that one in ten parents say their children have gone without asthma medication because of financial pressures.

NHS health expert Dr Ranj Singh has issued important advice to asthma sufferers who use a blue inhaler. The doctor appeared on today's (May 18) episode of BBC's Morning Live to urge people who rely on ...

Every year, millions welcome the monsoon with open arms as it brings relief from summer heat. However, for those living with ...